AzTrials
AzTrials

Parkinson DiseasePhase 1/2NCT05083260

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

A Phase 1/2 study testing NE3107 in people with Parkinson Disease, run by BioVie Inc. at 16 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Read more about this study

Who is it for?
Ages 30 to 80 years
Conditions the study is for
Parkinson Disease
What is being tested?
NE3107
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
46 participants
Where
16 sitesUnited States
Study dates
4 Jan 2022to 4 Jan 2023
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men or women at least 30 and no more 80 years of age
  • Diagnosis of PD consistent with UK Brain Bank Criteria or MDS Research Criteria for the Diagnosis of PD, with bradykinesia and a clear motor response to levodopa
  • Stable doses of all PD medications for at least 4 weeks prior to Screening
  • Carbidopa/levodopa dose of at least 300 mg daily, distributed over a minimum of 3 dosing intervals during waking hours
  • Participants must have history of motor fluctuations with reliable early-morning OFF episodes and a history of a good response to levodopa, in the judgement of the investigator
  • If of reproductive potential, willing and able to use a highly effective form of birth control during the study and for 30 days following last dose of study drug. Examples of highly effective forms of birth control are:
Show all 13Show fewer
  • Surgical sterility (via vasectomy, hysterectomy, or bilateral tubal ligation) or postmenopausal status in females
  • Sexual partner who is sterile or of the same sex
  • Double-barrier method (any combination of physical and chemical methods)
  • Intrauterine device in females not containing hormones.
  • Able and willing to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study
  • Investigational Review Board/Ethics Committee-approved consent form signed and date by the participant
  • Assessed as an appropriate and suitable candidate by the Enrollment Authorization Committee (EAC)

Who cannot join

  • Diagnosis of secondary or atypical parkinsonism
  • Severe or disabling fluctuations or dyskinesias that would, in the opinion of the investigator, interfere with completion of the study
  • Clinically significant cognitive impairment
  • Clinically significant hallucinations or delusions
  • Clinically significant orthostatic hypotension
  • Currently active major depression as determined by BDI-II score of >19
Show all 35Show fewer
  • Previous surgical procedure for PD (Duopa, DBS, etc.)
  • History of small bowel or gastric surgery
  • History of clinically significant GI abnormality (inflammatory bowel disease, significant motility disorder or emesis of any cause, etc.)
  • Use of long-acting levodopa formulations (Sinemet CR, ER, Rytary, etc.)
  • Routine use of proton pump inhibitors or H2 blockers
  • Routine use of medications that may influence gastric motility (opiates, TCA antidepressants, anticholinergics, etc.)
  • Other clinically significant medical, surgical, psychiatric, or laboratory abnormality that, in the judgment of the investigator, is likely to interfere with study compliance or assessment of safety or efficacy
  • 14) Evidence of significant hepatic impairment according to Child-Pugh criteria, history of cirrhosis, and/or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN), evidence of ascites, hepatic encephalopathy, bilirubin greater than 2 mg/dL, albumin less than 2.0 g/dL, and INR of 1.5 and greater
  • Significant renal impairment as determined by creatinine clearance (CrCL) less than or equal to 50 mL/min
  • Participant has an ECG or clinical evidence of potentially unstable heart disease, including the following:
  • QTcF > 470 msec females; > 450 msec males
  • Complete right or left bundle branch block
  • Ischemia or myocardial infarct within 1 year prior to the Screening Visit
  • Clinically significant atrial or ventricular dysrhythmia; the heart must be in predominantly normal sinus rhythm
  • Second- or third-degree AV block
  • Heart failure of NYHA classification III or greater
  • Serious cardiomyopathy or cardiac structural abnormality
  • Symptomatic coronary artery or ischemic cardiac disease
  • Any other cardiac condition that the Investigator feels may predispose the participant to ischemia or arrhythmia.
  • Current (or within past 12 months) diagnosis or history of substance abuse, including alcohol (excluding nicotine or caffeine) by Diagnostic and Statistical Manual of Mental Disorders 5 criteria, or positive urine drug screen for tetrahydrocannabinol or any drugs that may affect participant safety or interfere with efficacy assessments
  • Medical or recreational use of marijuana or CBD within 3 months of the Screening Visit
  • Active suicidal ideation within 1 year prior to Screening Visit as determined by a positive response to Question 4 or 5 on the C-SSRS
  • Currently lactating or pregnant, or planning to become pregnant during the study
  • Current participation in another investigational clinical study and/or receipt of any investigational drug within 90 days prior to screening
  • Prior randomization into this study
  • Diabetes requiring insulin treatment
  • Use of potent CYP3A4 inhibitors clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, and verapamil, and potent CYP2C9 and CYP2C19 inhibitors, amiodarone, fluconazole, miconazole, piperine, fluoxetine, fluvoxamine, and ticlopidine.
  • History of breast cancer
  • History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening. Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with efficacy assessments, based on the Investigator's clinical judgment.

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

United States16 sites

  • Parkinson's Disease & Movement Disorders Center Of Boca Raton

    Boca Raton, Florida, 33486

  • Duke University

    Durham, North Carolina, 27705

  • Rocky Mountain Movement Disorders Center

    Englewood, Colorado, 80113

  • Quest Research Institute

    Farmington Hills, Michigan, 48334

  • Velocity

    Hallandale, Florida, 33009

  • Charter Research

    Lady Lake, Florida, 32159

  • Premier Clinical Research Institute

    Miami, Florida, 33122

  • First Excellent Research Group

    Miami, Florida, 33172

  • First Excellent Research

    Miami, Florida, 33172

  • EZY Medical Research

    Miami, Florida, 33175

  • New York Neurology Associates

    New York, New York, 10003

  • M3 Wake Research

    Raleigh, North Carolina, 27612

  • Texas Institute for Neurological Disorders

    Sherman, Texas, 75092

  • Inland Northwest Research

    Spokane, Washington, 99202

  • University of Toledo

    Toledo, Ohio, 43614

  • Charter Research

    Winter Park, Florida, 32792

Other trials in United States

About this study

Official title: A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107

A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease . Study will enroll 40 patients that are currently taking immediate release levodopa/ carbidopa (IRLC) and have a practically defined early morning off-state for IRLC. Day one- baseline UPDRS and IRLC PK sampling; day 2- start NE3107 dosing, assess UPDRS during onset and NE3107 PK sampling, rescue meds as needed after 4 hours; day 3 and 14- NE3107 + IRLC UPDRS assessment and PK sampling; day 28- NE3107 + IRLC UPDRS assessments. Optional overnight stays in clinic prior to Day 1-3, 14, and 28.

Being tested
NE3107, placebo
Keywords
MDS-UPDRS
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NE3107Drug

    NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease

  • placeboDrug

    Hard gelatin capsule containing only common excipients for oral formulations

Study groups in NCT05083260
Study groupRoleWhat they receive
NE3107Experimentalorally administered NE3107 20 mg twice daily (BID)
Receives: Drug: NE3107
placeboPlacebo comparatororally administered placebo, twice daily
Receives: Drug: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours)

    Unified Parkinson's disease rating scale Part III total score is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each part scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease

    Measured: measured on day 1, 2, 3, 14, and 28

  2. Change from baseline in the length of time during which L-dopa therapy is ineffective in reducing motor symptoms of disease (OFF time)

    The total sum of time in which a patient self categorizes themselves as in the "off" state determined by diary entries. 0 hours is the minimum/best score, which indicates continuous L-dopa-like activity for the 24 hour period. 24 hours is the worst score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

    Measured: off time will be measured/recorded every day from day 2 to day 27

  3. Change from baseline in average Motor disease society- Unified Parkinson's disease rating scale Part III total score measured over the course of 8 hours after taking L-dopa and/or NE3107

    An average score will be calculated from assessments of the Unified Parkinson's disease rating scale Part III total score, which is the cumulative score of a 33 question assessment of disease impact on patient's ability to move, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 132 indicates the most severe disease. Scores will be collected several times during the eight hours following L-dopa and/or NE3107 administration.

    Measured: measured on day 1, 2, 3, 14, and 28

  4. Motor disease society- Unified Parkinson's disease rating scale Part I total score

    the cumulative score of a 13 question assessment of disease impact on patient's cognitive impairment, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being severe disease. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease. This test asks about the impact of disease on cognition, but does not directly measure cognitive capability.

    Measured: measured on day 1, 2, 3, 14, and 28

  5. Motor disease society- Unified Parkinson's disease rating scale Part 2 total score

    the cumulative score of a 13 question assessment of disease impact on patient's Motor Aspects of Experiences of Daily Living, with each question scored on a scale of 0-4, with 0 being no effect of disease and 4 being a severe effect. a total score of 0 indicates no disease and a total score of 42 indicates the most severe disease.

    Measured: measured on day 1, 2, 3, 14, and 28

  6. Change from baseline in the length of time during which L-dopa-like effects are felt by the patient

    The total sum of time in which a patient self categorizes themselves as in the "on" state, with or without dyskinesia determined by diary entries. 0 hours is the minimum/worst score, which indicates no L-dopa-like activity for the 24 hour period. 24 hours is the best score and indicates that there was no L-dopa-like benefit at any time during the 24 hour period.

    Measured: baseline and day 1, 2, 3, 14, and 28

  7. change from baseline in L-dopa induced dyskinesia measured with the abnormal involuntary movement scale (AIMS)

    AIMS is a 12-item clinician-rated scale to assess severity of dyskinesias (orofacial movements and extremity and truncal movements) in patients taking L-dopa. Questions assess the overall severity, incapacitation, and the patient's level of awareness of the movements, and distress associated with them. Questions are scored from 0 (no symptom) to 4 (severe). the minimum total score of 0 indicates no dyskinesia and the maximum total score of 48 indicates severe dyskinesia.

    Measured: AIMS will be measured during the 8 hour period of observation on Day 1, 2, 3, 14, and 28

  8. change from baseline in time to onset of L-dopa-like activity

    Length of time from L-dopa administration to beginning of L-dopa activity producing "on-state". Patient self assessment of the time L-dopa-like activity begins after L-dopa administration. A decrease in the time to onset may shorten the time in the off-state and be considered a patient benefit. An increase in time to onset may lengthen time in the off-state and be considered a general worsening of response to treatment.

    Measured: measured on Day 1, 2, 3, 14, and 28

  9. Change from baseline in Non-Motor Symptom Assessment Scale for Parkinson Disease (NMSS)

    The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients at all stages of PD. For each question, scores of severity (0 to 3, with 0 being none and 3 being major source of distress) and frequency (1 to 4, 1= rarely and 4 = very frequent) are recorded and the product of the two calculated. The sum of the products yields the overall score. The minimum total score of 0 indicates no non-motor symptoms and the maximum score of 360 indicates severe disease.

    Measured: Measured on Day 1, 2, 3, 14, and 28

  10. change in area under the levodopa plasma concentration vs. time curve when administered alone compared to being co-administered with NE3107

    the plasma concentration vs time curve for L-dopa will be calculated from the L-dopa concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa area under the curve could be associated with changes in activity against motor symptoms of disease.

    Measured: Blood samples will be collected on Day 1, 2, 3, and 14

  11. Change in the maximum plasma concentration (Cmax) of levodopa when administered alone compared to being co-administered with NE3107.

    the maximum plasma concentration for L-dopa will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after L-dopa administration on days on which NE3107 is not administered (Day 1) and three days on which NE3107 is co-administered (Day 2, 3, and 14). Changes in L-dopa Cmax could be associated with changes in activity against motor symptoms of disease.

    Measured: Blood samples will be collected on Day 1, 2, 3, and 14

  12. The area under the NE3107 plasma concentration vs. time curve when administered alone compared to being co-administered with

    the plasma concentration vs time curve for NE3107 will be calculated from the NE3107 concentration in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours

    Measured: Blood samples will be collected on Day 2, 3, and 14

  13. Change in the maximum plasma concentration (Cmax) of NE3107 when administered alone compared to being co-administered with L-dopa

    the maximum plasma concentration for NE3107 will be determined in plasma samples collected prior to dosing and at 0.5, 1, 2, 3, 4, and 8 hours after NE3107 administration

    Measured: Blood samples will be collected on Day 2, 3, and 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2021
  2. Study start4 Jan 2022
  3. Primary completion21 Nov 2022
  4. Study completion4 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
46 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05083260
Sponsor's protocol ID
NM201
Status last verified
Feb 2023
First submitted
23 Sep 2021
Last updated
8 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing NE3107 in people with Parkinson Disease, run by BioVie Inc. at 16 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline (day 1) in Motor disease society- Unified Parkinson's disease rating scale Part III total score for the patient in the "off-state" (without L-dopa for previous eight hours) (time frame: measured on day 1, 2, 3, 14, and 28). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05083260.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in